Idiopathic Short Stature Drug Market

Global Idiopathic Short Stature Drug Market Size, Share & Trends Analysis Report, By Product (BBT-031, MMP-0201, Somatropin, and Others), By Application (Hospital, Clinic, and Research Center), Forecast (2021-2027)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2026083 | Category : Pharmaceuticals | Delivery Format: /

The global idiopathic short stature drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Idiopathic short stature is defined as a condition in which the height of the individual is more than 2 standard deviations (SD) below the corresponding mean height for a given sex, age, and population, in whom no identifiable disorder persists. It can be subcategorized into familial and non-familial ISS, and according to pubertal delay. The market growth is attributed to the growing awareness amongst people about various hormone related disorders and thus, the rising number of growth hormone options available. Further, the growing prevalence of several genetic disorders such as Turner syndrome, Prader-Willi syndrome, and Noonan syndrome are also likely to provide a boost to the demand for idiopathic short stature drugs. Generally, there is no specific disorder of growth hormone (GH)/ insulin-like growth factor (IGF) and any other endocrine disorder, however in rare cases, idiopathic short stature can be associated with their cause.

Adding to this, the availability of insurance benefit in the developed economies such as the US further boosts the penetration of the biosimilar or biologics drugs used in the treatment of idiopathic short stature. While various treatment options are in the market majority of these are not approved for growth acceleration and hence, they are considered under off label use. Recombinant growth hormone therapy, Insulin like Growth Factor -1 (IGF-1) therapy, Aromatase inhibitors and low-dose androgen therapy (with injectable testosterone and low dose androgen) are some of the treatment options that have gain prominence in the past few years.

Market Coverage

The market number available for – 2020-2027

Base year- 2020

Forecast period- 2021-2027

Segment Covered- 

o By Product Type

o By Application

Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape:  Pfizer Inc., and Eli Lilly and Co., among others.

Key questions addressed by the report

What is the market growth rate?

Which segment and region dominate the market in the base year?

Which segment and region will project the fastest growth in the market?

How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?

How are players addressing challenges to sustain growth?

Where is the investment opportunity?

Global Idiopathic Short Stature Drug Market Report by Segment

By Product

BBT-031

MMP-0201

Somatropin

Others

By Application

Hospital

Clinic

Research Center

Global Idiopathic Short Stature Drug Market Report by Region

North America       

US

Canada

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia-Pacific    

China

Japan

India

Rest of Asia-Pacific

Rest of the World

Latin America

Middle East and Africa